



## The True Cost of Excluding Compounds

Topical compounded medications for the treatment of pain represent a significant percentage of payers' expenditure on compounded medications, averaging over \$1,300 per claim. In this study comparing the experience of two identical plans, Plan A is a national employer, mostly blue collar that saw a steady growth of compounds, and, Plan B, a highly managed union group that implemented a strict Prior Authorization for compounds at Quarter 4.



## Longitudinal view of pain spend

Average Pain-Related Medical Expense Per Patient by Quarter, Plans A and B



The results shows a 14% increase in pain-related medical expenditure for Plan B, 8% over the Plan A (6%). A longitudinal view of spending trend shows a clear spike in Plan B's pain-related medical spend between quarters 4 and 5, after the implementation of the strict PA criteria that essentially blocked all compounds.

Our Compounding Program Analysis exposes limitations in a payer's plan design and recommends customizable compounding management strategies that are focused on total cost of care and can be fully integrated into a the overall plan design strategy. Learn more at [www.personalmedrx.com](http://www.personalmedrx.com) and request information about the [compounding program analysis](#).